Health

New COVID treatment shows efficacy against omicron: Spain’s PharmaMar

Spain's PharmaMar said on Tuesday trials made in vitro and on animals showed its Plitidepsin drug had positive antiviral effects on the variants of COVID-19, including omicron.

The results of Phase I trials have shown the drug, also known as Aplidin, had a powerful antiviral activity against all the variants in vitro and a distribution into the lungs of animals tested, resulting in a 99 percent reduction of viral load in the lungs, the company said.

For more coronavirus news, visit our dedicated page.

The results of the trials were released in a paper published in the scientific journal Life Science Alliance, PharmaMar said.

The paper also reported positive effects of Phase I and II trials on patients.

"All data we have seen so far with Plitidepsin corroborate our initial hypothesis of its activity as antiviral," PharmaMar's Jose Maria Fernandez Sousa said in a statement.

The drug is being tested in final Phase III trials on patients.

Shares in PharmaMar rose 5.3 percent in early trading.

Plitidepsin is a drug developed by PharmaMar originally to treat cancer but has an effect as an antiviral.

Poland’s total COVID-19 death toll passes 100,000 amid fourth wave

‘Deltacron’ likely result of lab error: Experts

Health

World News in Brief: Vaccine ‘patches’ trial shows promise, lowering catheter infection risk, Guantanamo detainee facing revictimisation

Few enjoy having injections and if you have children, you probably like them even less when it’s time for their mandated vaccine shots.

Health

No sign yet of H5N1 bird flu spreading between humans, says WHO chief

The H5N1 avian influenza virus has so far shown no signs of adapting to allow human to human transmission, the UN health agency said on Wednesday, urging continued surveillance.

Health

Patients in Rafah ‘afraid to seek services’, WHO reports

The World Health Organization (WHO) has taken “crucial steps” in the event of a large-scale Israeli military operation in Rafah, Dr. Ahmed Dahir, Team Lead of its office in Gaza, told UN News on Tuesday.